Coronavirus
fromArs Technica
3 days agoOTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
An accessible azelastine nasal spray shows potential as a viral prophylactic despite a small, non-generalizable trial and constrained COVID-19 vaccine access in the US.